6-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 UNDER

THE SECURITIES EXCHANGE ACT OF 1934

For the Month of October 2020

Commission File Number: 001-38104

IMMURON LIMITED

(Name of Registrant)

Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒          Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes ☐      No ☒

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-

IMMURON LIMITED

EXPLANATORY NOTE

Immuron Limited (the “Company”) published two announcements (the “Public Notices”) to the Australian Securities Exchange on October 29, 2020 titled:

- “2020 AGM Presentation”

- “Results of Meeting”

A copy of the Public Notice is attached as an exhibit to this report on Form 6-K.

This report on Form 6-K (including the exhibit hereto) shall not be deemed to be “filed” for purposes of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

EXHIBITS

Exhibit Number	Description
99.1	2020 AGM Presentation
99.2	“Results of Meeting”

1

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	IMMURON LIMITED
Date:  October 29, 2020	By:	/s/ Phillip Hains
		Phillip Hains
		Company Secretary

2

EX-99.1

Exhibit 99.1

FORGING COMMERCIAL & CLINICAL PATHWAYS TARGETING INFECTIOUS DISEASES WITH ORAL IMMUNOTHERAPIES – OCTOBER, 2020 JERRY KANELLOS, Ph.D. CEO NASDAQ: IMRN ASX: IMC 1

DEVE L OPMENT PIPELINE 2

TRAVELAN® COMMERCIAL PROFILE: A UD $ - 3 $500,000 $1,000,000 $1,500,000 $2,000,000 $2,500,000 $3,000,000 FY17A FY18A FY19A FY20A $1.38M $2.01M $2.6M $2.7M Global Immuron Sales (Gross) - AUD

Plan to register Travelan® as a drug in the USA with the FDA to reduce the risk of Travelers’ Diarrhea (TD) in travelers to endemic areas: IMM - 124E DRUG DEVELOPMENT PLAN Execute Prevention Trial and File Registration Package 4 File IND with Plan for Double - Blind, Placebo Controlled Trial for Prevention of Travelers’ Diarrhea Hold Pre - IND Meeting to Discuss Merits of Application to Prevent TD Assimilate Data to Support IND Submission to FDA to Prevent TD x x

US SALES FORECAST FOR TRAVELAN®: IF APPROVED AS DRUG Market potential figure derived from: 2014 figures of US citizens traveling to high risk destinations for TD (44.3 million) 1 and obtaining pretravel advice (22.2 million) 2 . Sources of pre - travel advice include primary care provider, travel medicine specialist, company doctors, pharmacist, and travel agencies 2 . Our forecast utilizes a very conservative estimate for % of US citizens purchasing Travelan® after seeking pre - travel advice. 1. U.S. Department of Commerce, International Trade Administration, National Travel and Tourism Office. U.S. Citizen Traffic to Overseas Regions, Canada & Mexico 2014. Monthly Statistics, U.S.Outbound Travel by World Regions. 2014. Available at: http://travel.trade.gov/view/m - 2014 - O - 001/index.html. Accessed June 26, 2015. 2. Mathyas Wang , MD , Thomas D. Szucs , MD, MBA, MPH, LLM , and Robert Steffen , MD. Economic Aspects of Travelers ’ Diarrhea. Journal of Travel Medicine, Volume 15, Issue 2, 2008, 110 – 118 MARKET POTENTIAL FOR TRAVELAN® SALES: USD >$100 MILLION 5

A RANDOMIZED, DOUBLE - BLIND, PLACEBO - CONTROLLED TRIAL EVALUATING THE EFFICACY OF NON - ANTIBIOTIC OTC PRODUCTS IN TRAVELERS’ DIARRHEA (TD) PREVENTION (P4TD) 6 CURRENT STATUS – PLAN TO C 0 MMENCE ENROLMENT JUNE 2021 Primary Objective : To evaluate the clinical efficacy of Travelan®, Florastor® and Bimuno® vs . placebo for maintenance of Gastrointestinal Health (GH) focusing on a 10 day window of prophylaxis during travel . STUDY DESIGN This is a randomized ( 1 : 1 : 1 : 1 allocation), double - blind, placebo controlled multicenter clinical trial comparing three dietary supplements, Travelan®, Florastor® and Bimuno®, individually against placebo to determine efficacy for maintenance of GH . A total of 1320 subjects ( 330 /arm) will be enrolled from the following populations : active duty US and UK military personnel, US DoD beneficiaries and US civilians deploying or traveling to intermediate or high GH disruption risk destinations .

Two Human Clinical Trials Planned: New Drug to Reduce the risk of Infectious Diarrhea Caused by Campylobacter and by ETEC US NAVEL MEDICAL RESEARCH CENTRE DRUG DEVELOPMENT PLAN Execute Prevention Trials 7 File IND with Plans for two Double - Blind, Placebo Controlled Prevention Trials Hold Pre - IND Meeting to Discuss Merits of Application to Prevent TD Assimilate Data to Support IND Submission to FDA to Prevent TD x x

Develop clinical protocol for FDA approval as drug to prevent recurrent Clostridiodes difficile Infection: IMM - 529 DRUG DEVELOPMENT PLAN Execute recurrence prevention trial 8 File IND with plan for placebo controlled trial for prevention of disease recurrence Hold pre - IND meeting to discuss clinical protocol and strategy Develop clinical registration strategy for FDA submission

Immuron Reports Neutralizing activity Against SARS - CoV - 2 9 Key Points Immuron’s Hyper - immune Bovine Colostrum used to manufacture Travelan® and Protectyn® demonstrates antiviral activity against the COVID - 19 virus in laboratory studies Immuron’s technology platform offers a potential new oral therapeutic approach to target SARS - CoV - 2 in the GI Tract Melbourne, Australia, July 21, 2020: Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercialising oral immunotherapeutics for the prevention and treatment of gut mediated pathogens, today is pleased to announce that the hype - Immune bovine colostrum used to manufacture the company’s flag ship commercially available and over - the - counter gastrointestinal and digestive health immune supplements Travelan® and Protectyn® has demonstrated neutralizing activity against the severe acute respiratory syndrome coronavirus - 2 (SARS - CoV - 2), the virus that causes COVID - 19.

IMM - 124E SARS - COV - 2 RESEARCH & DEVELOPMENT PROPOSAL 10 CURRENT STATUS RESEARCH & DEVELOPMENT Reached out to local, national, and international potential research collaborators to advance this work and assist in the further characterization of the neutralization activity of SARS - CoV - 2 observed with IMM - 124E • Research Services Agreements » To identify the inhibitory substance/s in IMM - 124E • Preclinical Development » Access application form for a contract research project – submitted » The project aims to assess the effect of IMM - 124E in ex - vivo and animal models infected with SARS - CoV - 2

IMM - 124E SARS - COV - 2 RESEARCH & DEVELOPMENT PROPOSAL 11 CURRENT STATUS CLINICAL PROPOSALS • Consultancy agreement executed with Professor Teena Chopra, Professor of Medicine Wayne State University School of Medicine, Detroit » Professor Chopra is building a registry of the patients presenting with gastrointestinal events to better understand this cohort and the unique medical challenges they present • Clinical protocol development » Reviewing several proposals to assess the efficacy of IMM - 124E to treat patients with COVID - 19

EX-99.2

Exhibit 99.2

 

IMMURON LIMITED

(ASX: IMC)

Thursday, 29^th October 2020: Results of Annual General Meeting

Immuron Limited (ASX: IMC; NASDAQ: IMRN) wishes to advise that all resolutions were carried by a poll.

In accordance with Listing Rule 3.13.2 and Section 251AA of the Corporations Act 2001, we advise details of the resolutions and the proxies received in respect of each resolution are set out in the attached proxy summary.

The Chairman voted undirected proxies in his control in favour of all resolutions.

Resolution 1 and 8 require 75% approval to be passed. This threshold has been achieved and the resolutions passed.

On behalf of the Board;

Phillip Hains

Company Secretary

Level 3, 62 Lygon Street	www.immuron.com	Phone:      + 61 (0)3 9824 5254
Carlton, Victoria	ABN: 80 063 114 045	Facsimile: + 61 (0)3 9822 7735
AUSTRALIA  3053

Disclosure of Proxy Votes
Immuron Limited	GPO Box 5193, Sydney, NSW 2001
Annual General Meeting	P 1300 288 664 (aus) or +61 (0)2 9698 5414 (world)
Thursday, 29 October 2020	F +61 (0)2 8583 3040 E hello@automic.com.au
	ABN 27 152 260 814

In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to members at the meeting.

	Decided by Show of Hands		Total Number of Proxy Votes exercisable by proxies	Proxy Votes									Poll Results (if applicable)
Resolution	(S) or Poll (P)	validly appointed		FOR		AGAINST			ABSTAIN		PROXY’S DISCRETION		FOR		AGAINST			ABSTAIN
1 NON-BINDING RESOLUTION TO ADOPT REMUNERATION REPORT	P		30,767,612	26,637,225 86.58	%		3,705,243 12.04	%		229,240	425,144 1.38	%	27,062,369 87.96	%		3,705,243 12.04	%		229,240
2 RE-ELECTION OF DR ROGER ASTON AS A DIRECTOR	P		44,524,532	40,621,909 91.23	%		3,677,479 8.26	%		82,583	225,144 0.51	%	40,847,053 91.74	%		3,677,479 8.26	%		82,583
3 RATIFICATION OF PRIOR ISSUE OF SHARES - PUBLIC OFFERING OF ADSs	P		41,592,055	37,177,128 89.39	%		4,189,783 10.07	%		289,860	225,144 0.54	%	37,402,272 89.93	%		4,189,783 10.07	%		289,860
4 APPROVAL TO REFRESH EXECUTIVE SHARE OPTION PLAN	P		32,076,992	26,527,474 82.70	%		5,124,374 15.98	%		965,220	425,144 1.33	%	26,952,618 84.02	%		5,124,374 15.98	%		965,220
5 ADOPTION OF NON-EXECUTIVE DIRECTOR REMUNERATION POOL	P		31,281,832	26,469,923 84.62	%		4,386,765 14.02	%		517,380	425,144 1.36	%	26,895,067 85.98	%		4,386,765 14.02	%		517,380
6a APPROVAL TO ISSUE SHARES TO A DIRECTOR – DR ROGER ASTON	P		32,152,392	26,454,723 82.28	%		5,262,525 16.37	%		1,367,296	435,144 1.35	%	26,889,867 83.63	%		5,262,525 16.37	%		1,367,296
6b APPROVAL TO ISSUE SHARES TO A DIRECTOR – MR DANIEL POLLOCK	P		32,210,912	26,454,723 82.13	%		5,321,045 16.52	%		711,700	435,144 1.35	%	26,889,867 83.48	%		5,321,045 16.52	%		711,700

	Decided by Show of Hands	Total Number of Proxy Votes exercisable by proxies		Proxy Votes									Poll Results (if applicable)
Resolution	(S) or Poll (P)	validly appointed		FOR		AGAINST			ABSTAIN		PROXY’S DISCRETION		FOR		AGAINST			ABSTAIN
6c APPROVAL TO ISSUE SHARES TO A DIRECTOR – PROF. RAVI SAVARIRAYAN	P		32,183,112	26,457,123 82.21	%		5,290,845 16.44	%		740,060	435,144 1.35	%	26,892,267 83.56	%		5,290,845 16.44	%		740,060
6d APPROVAL TO ISSUE SHARES TO A DIRECTOR – MR STEPHEN ANASTASIOU	P		30,145,213	24,390,944 80.91	%		5,319,125 17.65	%		10,815,039	435,144 1.44	%	24,826,088 82.35	%		5,319,125 17.65	%		10,815,039
6e APPROVAL TO ISSUE SHARES TO A DIRECTOR – MR PETER ANASTASIOU	P		30,144,653	24,390,944 80.91	%		5,318,565 17.64	%		7,709,681	435,144 1.44	%	24,826,088 82.36	%		5,318,565 17.64	%		7,709,681
7a APPROVAL TO ISSUE OPTIONS TO DR ROGER ASTON	P		32,201,592	26,479,159 82.23	%		5,287,289 16.42	%		1,656,096	435,144 1.35	%	26,914,303 83.58	%		5,287,289 16.42	%		1,656,096
7b APPROVAL TO ISSUE OPTIONS TO MR DANIEL POLLOCK	P		32,177,352	26,476,759 82.28	%		5,265,449 16.36	%		960,500	435,144 1.35	%	26,911,903 83.64	%		5,265,449 16.36	%		960,500
7c APPROVAL TO ISSUE OPTIONS TO PROF. RAVI SAVARIRAYAN	P		32,118,792	26,479,159 82.44	%		5,204,489 16.20	%		1,018,500	435,144 1.35	%	26,914,303 83.80	%		5,204,489 16.20	%		1,018,500
7d APPROVAL TO ISSUE OPTIONS TO MR STEPHEN ANASTASIOU	P		30,107,853	24,409,180 81.07	%		5,263,529 17.48	%		11,070,799	435,144 1.45	%	24,844,324 82.52	%		5,263,529 17.48	%		11,070,799
7e APPROVAL TO ISSUE OPTIONS TO MR PETER ANASTASIOU	P		30,056,973	24,409,180 81.21	%		5,212,649 17.34	%		8,017,801	435,144 1.45	%	24,844,324 82.66	%		5,212,649 17.34	%		8,017,801
8 APPROVAL OF 10% PLACEMENT FACILITY	P		44,234,332	38,748,514 87.60	%		5,250,674 11.87	%		372,783	235,144 0.53	%	38,983,658 88.13	%		5,250,674 11.87	%		372,783